ArticleNPJ precision oncology2026
Dissecting non-small cell lung cancer (NSCLC) with blood proteomics-from surgical to immunotherapeutic responses.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
NSCLC remains a leading cause of cancer-related mortality, with limited biomarkers to guide surgical and immunotherapeutic intervention. This study leveraged two complementary plasma proteomics platforms, SomaScan (7596 proteins) and NULISA (250 inflammation-related proteins) to profile 87 timepoints from 56 NSCLC patients, collected pre- and post-surgery and pre- and post-ICI therapy. Robust biomarker selection used adaptive Lasso regression and the Stabl algorithm, with inter- and intra-cohort validation via orthogonal nELISA proteomics. Twenty-one differentially detectable plasma proteins were identified across treatment contexts. Surgical resection induced measurable proteomic changes: non-recurrent patients had higher circulating MUC16 and lower IL36G post-surgery, while recurrent patients showed elevated COX7A2L, FGF19, and SPOCK2, alongside lower FCER2, FCRLA, and SLITRK2. Among ICI-treated patients, responders had lower baseline levels of IL-6, CCL19, IL-2RA, CD200R1, CRP, LIF, PDCD1, CCL7, and SPP1, implicating systemic inflammation and immune regulation in treatment sensitivity. CEACAM5, PTX3, FGF23, and AREG were elevated in patients with worse clinical outcomes and poorer overall survival. MUC16, IL36G, CCL19, and IL-6 were independently validated by nELISA. Cross-platform comparison highlighted the complementary strengths of SomaScan's broad proteomic coverage and NULISA's sensitivity for low-abundance proteins. This integrated approach reveals distinct plasma signatures associated with surgical recurrence, ICI response, and prognosis in NSCLC.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.